Henry named company's director
Former Gov. Brad Henry has been elected as a director of CFS2, a Tulsa-based debt-collection company. Henry's will be involved in “the strategic planning and capital planning process,” the company said. “CFS2 is a remarkable opportunity to create an entirely new blend of consumer service and social impact,” Henry said. Bill Bartmann, founder and CEO of CFS2, said, “I am convinced we are on the right track to reforming an industry of rampant abuse and Gov. Henry will play a big role in helping to deliver our message to regulators and capital sources. His commitment to be a part of our company is proof of his belief that what we are doing is important and that we have the ability to change millions of lives.” After his terms as governor, Henry retired to private life and, along with his former chief of staff Gerald Adams, formed the Henry Adams Companies to provide consulting and strategic planning services and legal counsel.
OKC firm involved in clinical trial
Oklahoma City-based Altheus Therapeutics Inc., said Thursday it has completed enrollment for a six-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa Rectal Gel in about 120 adult patients with left-sided, or distal, ulcerative colitis. Top line results are expected to be available in March or early April, the company said. Altheus CEO Dennis Schafer said, “We look forward to gaining alignment on our registration program with the FDA (Food and Drug Administration) and other health authorities as the next step to making Zoenasa available to IBD (inflammatory bowel disease) patients.” Nearly 1.2 million Americans suffer from inflammatory bowel disease. Zoenasa is a patented combination of two FDA-approved drugs that have been shown to act together to improve the signs and symptoms of ulcerative colitis.
From Staff Reports